Information Provided By:
Fly News Breaks for July 13, 2015
EW
Jul 13, 2015 | 07:02 EDT
RBC Capital upgraded Edwards Lifesciences to Outperform and increased its price target to $185 from $135. The firm raised its WW TAVR market estimates for 2020 to $5B from $3.5B on increased confidence in Partner IIa study results expected at ACC in April 2016. The firm's consultants believes expansion into intermediate risk patients will expand the market for WW TAVR by 2-3x and expects the FDA to approve label expansion for Sapien valved into intermediate-risk patients in late 2016/early 2017.